UK markets close in 5 hours 30 minutes
  • FTSE 100

    6,920.44
    +38.85 (+0.56%)
     
  • FTSE 250

    17,076.10
    +285.70 (+1.70%)
     
  • AIM

    801.80
    +3.41 (+0.43%)
     
  • GBP/EUR

    1.1386
    +0.0062 (+0.55%)
     
  • GBP/USD

    1.1157
    +0.0034 (+0.30%)
     
  • BTC-GBP

    17,490.08
    -47.70 (-0.27%)
     
  • CMC Crypto 200

    446.30
    +0.32 (+0.07%)
     
  • S&P 500

    3,640.47
    -78.57 (-2.11%)
     
  • DOW

    29,225.61
    -458.13 (-1.54%)
     
  • CRUDE OIL

    81.83
    +0.60 (+0.74%)
     
  • GOLD FUTURES

    1,677.40
    +8.80 (+0.53%)
     
  • NIKKEI 225

    25,937.21
    -484.84 (-1.83%)
     
  • HANG SENG

    17,222.83
    +56.96 (+0.33%)
     
  • DAX

    12,063.70
    +88.15 (+0.74%)
     
  • CAC 40

    5,716.13
    +39.26 (+0.69%)
     

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

·1-min read

LONDON, May 18, 2022--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.

The on-demand presentation will be available beginning on Monday, May 23 at 7:00am ET / 12:00pm GMT and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005052/en/

Contacts

Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208